|

Purinergic Signaling and the Postmenopausal Heart

RECRUITINGSponsored by Beth Israel Deaconess Medical Center
Actively Recruiting
SponsorBeth Israel Deaconess Medical Center
Started2019-07-01
Est. completion2025-06
Eligibility
Age30 Years – 88 Years
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT06015776

Summary

There is an increased risk of diastolic heart failure in post menopausal women. Estrogen plays a positive role in regulating molecular pathways in heart remodeling. Such pathways may work through purinergic signaling and its downstream effects on the heart's mitochondrial metabolism and angiogenic response to stress. Loss of estrogen functionality in post menopausal women may account for the increased risk of diastolic heart failure. The investigators will explore said pathways using cardiac tissue obtained from patients undergoing cardiac surgery.

Eligibility

Age: 30 Years – 88 YearsHealthy volunteers accepted
Inclusion Criteria:

* Patients undergoing cardiac surgery under cardiopulmonary bypass.

Exclusion Criteria:

* Refusal to participate
* Emergency surgery
* Pre-existing heart block
* Preexisting atrial fibrillation
* Redo surgery
* Estrogen or hormone replacement therapy
* History of chronic heart failure
* History of major kidney disease

Conditions3

Diastolic Heart FailureHeart DiseaseHeart Failure With Preserved Ejection Fraction

Locations1 site

Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215
Robina Matyal, MD617-640-1208rmatyal1@bidmc.harvard.edu

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.